Vora and coauthors investigated whether organ transplantation was the source of rabies virus
exposure in a kidney recipient who died 18 months after transplantation. They then evaluated for and
prevented rabies in other transplant recipients from the same donor. In an Editorial, Kaul discusses
the implications for improving the safety of solid organ transplantation.
This open-label uncontrolled study of patients with chronic HCV genotype 1 infection and cirrhosis reports high rates of SVR12 in those who received a 12-week oral fixed-dose regimen of daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin.
This randomized trial reports a lower incidence of hepatitis B virus (HBV) infection and reactivation in patients seropositive for the hepatitis B surface antigen with untreated diffuse large B-cell lymphoma receiving treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
The PHOTON-1 investigators report that, after 12 or 24 weeks of treatment patients coinfected with HIV and hepatitis C virus who received an oral, interferon-free combination of sofosbuvir and ribavirin for 12 or 24 weeks had high rates of sustained virologic response.
This randomized trial reports high rates of sustained virologic response in the first part of a open-label study of ombitasvir, paritaprevir (co-dosed with ritonavir), and dasabuvir with ribavirin for 63 patients with hepatitis C virus genotype 1 and human immunodeficiency virus 1 co-infection.
To assess the addition of sofosbuvir to ribavirin to treat liver disease in patients with hepatitis C virus, especially among patients with unfavorable treatment characteristics—black race, genotype 1a, advanced liver fibrosis, and obesity—Osinusi and coauthors conducted a 2-part, single-center, randomized open-label trial involving 60 patients. They compared the combination treatment of weight-based or low-dose ribavirin treatment plus 400 mg/d of sofosbuvir for 24 weeks.